Claims for Patent: 9,075,057

Summary for Patent: 9,075,057

Title:	Competition-based detection assays
Abstract:	Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme\'s ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.
Inventor(s):	Roseman; Daniel S. (Framingham, MA)
Assignee:	Shire Human Genetic Therapies, Inc. (Lexington, MA)
Application Number:	14/124,979
Patent Claims:	1. A method for detecting the relative amount of glycan associated with an enzyme in a test sample, wherein said method comprises the steps of: (a) contacting said test sample with at least one capture agent under conditions appropriate for binding of glycosylated enzyme in said test sample to said capture agent, wherein if said glycosylated enzyme is present in said test sample a bound enzyme is formed; (b) separating said bound enzyme from said test sample; and (c) detecting the extent to which said bound enzyme inhibits binding of a ligand to said capture agent, wherein the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is indicative of the relative amount of glycan associated with said enzyme in said test sample; wherein said capture agent comprises a fusion protein, and wherein said fusion protein comprises M6PR binding domain 9. 2. The method of claim 1, wherein said fusion protein comprises six consecutive histidine residues (6His). 3. The method of claim 1, wherein the step of detecting the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is performed by contacting said bound enzyme with said ligand. 4. The method of claim 3, wherein said ligand is a competitive inhibitor which competes with an enzyme suspected of being present in said test sample for binding to said capture agent. 5. The method of claim 4, wherein said enzyme is idursulfase and said competitive inhibitor is agalsidase alfa. 6. The method of claim 4, wherein said enzyme is heparan N-sulfatase and said competitive inhibitor is agalsidase alfa. 7. The method of claim 4, wherein said enzyme is aryl sulfatase A and said competitive inhibitor is agalsidase alfa. 8. The method of claim 1, wherein the greater the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is indicative of a greater relative amount of glycan associated with said enzyme in said test sample, and wherein the lesser the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is indicative of a lesser relative amount of glycan associated with said enzyme in said test sample. 9. The method of claim 3, wherein the step of detecting the extent to which said bound enzyme inhibits binding of said ligand to said capture agent comprises determining the amount of said ligand bound to said capture agent. 10. The method of claim 9, wherein the step of determining the amount of said ligand bound to said capture agent comprises detecting the intrinsic enzymatic activity of said ligand bound to said capture agent. 11. The method of claim 10, wherein the step of detecting intrinsic enzymatic activity of said ligand bound to said capture agent is performed by contacting said ligand bound to said capture agent with a substrate. 12. The method of claim 11, wherein said substrate is reactive with said ligand bound to said capture agent. 13. The method of claim 11, wherein the conversion of said substrate to product is indicative of intrinsic enzymatic activity. 14. The method of claim 10, wherein the step of detecting intrinsic enzymatic activity comprises quantitatively determining the presence of a product formed after contacting said ligand bound to said capture agent with said substrate. 15. The method of claim 14, wherein the presence of said product is indicative of intrinsic enzymatic activity. 16. The method of claim 11, wherein said ligand is agalsidase alfa and said substrate is 4-nitrophenyl-.alpha.-D-galactopyranoside. 17. The method of claim 1, wherein said enzyme is idursulfase and said glycan is sialic acid. 18. The method of claim 1, wherein said enzyme is idursulfase and said glycan is mannose-6-phosphate. 19. The method of claim 1, wherein said enzyme is heparan N-sulfatase and said glycan is sialic acid. 20. The method of claim 1, wherein said enzyme is heparan N-sulfatase and said glycan is mannose-6-phosphate. 21. The method of claim 1, wherein said enzyme is aryl sulfatase A and said glycan is sialic acid. 22. The method of claim 1, wherein said enzyme is aryl sulfatase A and said glycan is mannose-6-phosphate. 23. The method of claim 1, wherein the step of separating said bound enzyme from said test sample is performed by washing. 24. A method for detecting the relative amount of glycan associated with an enzyme in a test sample, wherein said method comprises the steps of: (a) contacting a test sample with at least one capture agent under conditions appropriate for binding of glycosylated enzyme, wherein if said glycosylated enzyme is present in said test sample a bound enzyme is formed; (b) separating said bound enzyme from said test sample; (c) contacting said bound enzyme with at least one ligand for said capture agent; and (d) detecting the extent to which said bound enzyme inhibits binding of said ligand to said capture agent, wherein the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is indicative of the relative amount of glycan associated with said enzyme in said test sample; wherein said capture agent comprises is a fusion protein, and wherein said fusion protein comprises M6PR binding domain 9. 25. The method of claim 24, wherein said fusion protein comprises six consecutive histidine residues (6His). 26. The method of claim 24, wherein said ligand is a competitive inhibitor which competes with an enzyme suspected of being present in the test sample for binding to said capture agent. 27. The method of claim 26, wherein said enzyme is idursulfase and said competitive inhibitor is agalsidase alfa. 28. The method of claim 26, wherein said enzyme is heparan N-sulfatase and said competitive inhibitor is agalsidase alfa. 29. The method of claim 26, wherein said enzyme is aryl sulfatase A and said competitive inhibitor is agalsidase alfa. 30. The method of claim 24, wherein the greater the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is indicative of a greater relative amount of said glycan associated with said enzyme glycoform in said test sample, and wherein the lesser the extent to which said bound enzyme inhibits binding of said ligand to said capture agent is indicative of a lesser relative amount of glycan associated with said enzyme glycoform in said test sample. 31. The method of claim 24, wherein the step of detecting the extent to which said bound enzyme inhibits binding of said ligand to said capture agent comprises determining the amount of said ligand bound to said capture agent. 32. The method of claim 31, wherein the step of determining the amount of said ligand bound to said capture agent comprises detecting the intrinsic enzymatic activity of said ligand bound to said capture agent. 33. The method of claim 32, wherein the step of detecting intrinsic enzymatic activity of said ligand bound to said capture agent is performed by contacting said ligand bound to said capture agent with a substrate. 34. The method of claim 33, wherein said substrate is reactive with said ligand bound to said capture agent. 35. The method of claim 33, wherein the conversion of said substrate to product is indicative of intrinsic enzymatic activity. 36. The method of claim 32, wherein the step of detecting intrinsic enzymatic activity comprises quantitatively determining the presence of a product formed after contacting said ligand bound to said capture agent with said substrate. 37. The method of claim 36, wherein the presence of said product is indicative of intrinsic enzymatic activity. 38. The method of claim 33, wherein said ligand is agalsidase alfa and said substrate is 4-nitrophenyl-.alpha.-D-galactopyranoside. 39. The method of claim 24, wherein said enzyme is idursulfase and said glycan is sialic acid. 40. The method of claim 24, wherein said enzyme is idursulfase and said glycan is mannose-6-phosphate. 41. The method of claim 24, wherein said enzyme is heparan N-sulfatase and said glycan is sialic acid. 42. The method of claim 24, wherein said enzyme is heparan N-sulfatase and said glycan is mannose-6-phosphate. 43. The method of claim 24, wherein said enzyme is aryl sulfatase A and said glycan is sialic acid. 44. The method of claim 24, wherein said enzyme is aryl sulfatase A and said glycan is mannose-6-phosphate. 45. The method of claim 24, wherein said bound enzyme is separated from said test sample by washing. 46. A kit for detecting the relative amount of glycan associated with an glycosylated enzyme in a test sample, wherein said kit comprises (a) at least one capture agent, wherein said capture agent is capable of binding said glycosylated enzyme, and (b) at least one ligand, wherein said ligand is competitive with said glycosylated enzyme for binding said at least one capture agent; wherein said capture agent is a fusion protein, and wherein said fusion protein comprises M6PR binding domain 9. 47. The kit of claim 46, wherein said fusion protein comprises six consecutive histidine residues (6His). 48. The kit of claim 46, wherein said kit further comprises a solid support. 49. The kit of claim 46, wherein said capture agent is affixed onto said solid support. 50. The kit of claim 46, wherein said glycosylated enzyme is selected from the group consisting of idursulfase, heparan N-sulfatase, and aryl sulfatase A. 51. The kit of claim 46, wherein said ligand is agalsidase alfa. 52. The kit of claim 46, wherein said ligand is agalsidase alfa, and said glycosylated enzyme is selected from the group consisting of idursulfase, heparan N-sulfatase, and aryl sulfatase A. 53. The kit of claim 46, further comprising a substrate. 54. The kit of claim 53, wherein said substrate is 4-nitrophenyl-.beta.-D-galactopyranoside. 55. The kit of claim 46, wherein said kit further comprises a means to separate said bound enzyme from said test sample.

Details for Patent 9,075,057

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	ELAPRASE	idursulfase	Injection	125151	07/24/2006		2031-06-08